Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897372177> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2897372177 endingPage "1421" @default.
- W2897372177 startingPage "1419" @default.
- W2897372177 abstract "Management of patients with newly diagnosed mantle cell lymphoma is fairly well established. For younger patients, treatment involves high-dose cytarabine-based chemotherapy, which is usually consolidated with stem-cell transplantation and rituximab maintenance therapy. For older patients, in whom high-intensity therapy is inappropriate, immuno-chemotherapy is the treatment of choice, and is usually based on either CHOP-based (cyclophosphamide, doxorubicin, vincristine, and prednisone) or bendamustine-based therapies. Because the average age at presentation for mantle cell lymphoma is around 70 years, most patients fall within the latter group. Very few randomised trials have been done in mantle cell lymphoma, and therefore data to inform best practice are scarce. Furthermore, the trials that have been done were subset analyses of larger trials or often underpowered. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 studyIn the LYM-3002 study, the efficacy and safety of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were compared in transplant-ineligible patients with untreated, newly diagnosed, mantle cell lymphoma. We report the final overall survival and safety outcomes for patients in the long-term follow-up phase after the primary progression-free-survival endpoint was met. Full-Text PDF" @default.
- W2897372177 created "2018-10-26" @default.
- W2897372177 creator A5059022907 @default.
- W2897372177 date "2018-11-01" @default.
- W2897372177 modified "2023-10-16" @default.
- W2897372177 title "Bortezomib-based chemotherapy in mantle cell lymphoma" @default.
- W2897372177 cites W2013412242 @default.
- W2897372177 cites W2056952913 @default.
- W2897372177 cites W2147422161 @default.
- W2897372177 cites W2158945674 @default.
- W2897372177 cites W2169209759 @default.
- W2897372177 cites W2177017987 @default.
- W2897372177 cites W2558107043 @default.
- W2897372177 cites W2760635695 @default.
- W2897372177 doi "https://doi.org/10.1016/s1470-2045(18)30743-5" @default.
- W2897372177 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30348536" @default.
- W2897372177 hasPublicationYear "2018" @default.
- W2897372177 type Work @default.
- W2897372177 sameAs 2897372177 @default.
- W2897372177 citedByCount "6" @default.
- W2897372177 countsByYear W28973721772019 @default.
- W2897372177 countsByYear W28973721772020 @default.
- W2897372177 countsByYear W28973721772021 @default.
- W2897372177 countsByYear W28973721772022 @default.
- W2897372177 crossrefType "journal-article" @default.
- W2897372177 hasAuthorship W2897372177A5059022907 @default.
- W2897372177 hasConcept C126322002 @default.
- W2897372177 hasConcept C141071460 @default.
- W2897372177 hasConcept C143998085 @default.
- W2897372177 hasConcept C2776364478 @default.
- W2897372177 hasConcept C2776694085 @default.
- W2897372177 hasConcept C2776755627 @default.
- W2897372177 hasConcept C2777478702 @default.
- W2897372177 hasConcept C2777525834 @default.
- W2897372177 hasConcept C2778720950 @default.
- W2897372177 hasConcept C2779050716 @default.
- W2897372177 hasConcept C2779338263 @default.
- W2897372177 hasConcept C2779429289 @default.
- W2897372177 hasConcept C2779725641 @default.
- W2897372177 hasConcept C2780653079 @default.
- W2897372177 hasConcept C2781442060 @default.
- W2897372177 hasConcept C71924100 @default.
- W2897372177 hasConceptScore W2897372177C126322002 @default.
- W2897372177 hasConceptScore W2897372177C141071460 @default.
- W2897372177 hasConceptScore W2897372177C143998085 @default.
- W2897372177 hasConceptScore W2897372177C2776364478 @default.
- W2897372177 hasConceptScore W2897372177C2776694085 @default.
- W2897372177 hasConceptScore W2897372177C2776755627 @default.
- W2897372177 hasConceptScore W2897372177C2777478702 @default.
- W2897372177 hasConceptScore W2897372177C2777525834 @default.
- W2897372177 hasConceptScore W2897372177C2778720950 @default.
- W2897372177 hasConceptScore W2897372177C2779050716 @default.
- W2897372177 hasConceptScore W2897372177C2779338263 @default.
- W2897372177 hasConceptScore W2897372177C2779429289 @default.
- W2897372177 hasConceptScore W2897372177C2779725641 @default.
- W2897372177 hasConceptScore W2897372177C2780653079 @default.
- W2897372177 hasConceptScore W2897372177C2781442060 @default.
- W2897372177 hasConceptScore W2897372177C71924100 @default.
- W2897372177 hasIssue "11" @default.
- W2897372177 hasLocation W28973721771 @default.
- W2897372177 hasLocation W28973721772 @default.
- W2897372177 hasOpenAccess W2897372177 @default.
- W2897372177 hasPrimaryLocation W28973721771 @default.
- W2897372177 hasRelatedWork W2027653372 @default.
- W2897372177 hasRelatedWork W2058154950 @default.
- W2897372177 hasRelatedWork W2526961449 @default.
- W2897372177 hasRelatedWork W2935716814 @default.
- W2897372177 hasRelatedWork W2989344576 @default.
- W2897372177 hasRelatedWork W3046714011 @default.
- W2897372177 hasRelatedWork W319232779 @default.
- W2897372177 hasRelatedWork W4236815493 @default.
- W2897372177 hasRelatedWork W4244051174 @default.
- W2897372177 hasRelatedWork W4250202452 @default.
- W2897372177 hasVolume "19" @default.
- W2897372177 isParatext "false" @default.
- W2897372177 isRetracted "false" @default.
- W2897372177 magId "2897372177" @default.
- W2897372177 workType "article" @default.